905592-33-8

Basic information

• Product Name: 4-(3-ETHOXYPHENYL)-4-OXOBUTYRIC ACID
• Synonyms: 4-(3-ETHOXYPHENYL)-4-OXOBUTYRIC ACID
• CAS NO: 905592-33-8
• Molecular Formula: C₁₂H₁₄O₄
• Molecular Weight: 222.24
• Mol File: 905592-33-8.mol

Chemical Properties

• Boiling Point: 400.4°C at 760 mmHg
• Flash Point: 154.9°C
• Appearance: /
• Density: 1.175g/cm³
• Vapor Pressure: 3.95E-07mmHg at 25°C
• Refractive Index: 1.53
• PKA: 4.52±0.17(Predicted)
• CAS DataBase Reference: 4-(3-ETHOXYPHENYL)-4-OXOBUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-ETHOXYPHENYL)-4-OXOBUTYRIC ACID(905592-33-8)
• EPA Substance Registry System: 4-(3-ETHOXYPHENYL)-4-OXOBUTYRIC ACID(905592-33-8)

Safety Data

• Hazardous Substances Data: 905592-33-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14O4/c1-2-16-10-5-3-4-9(8-10)11(13)6-7-12(14)15/h3-5,8H,2,6-7H2,1H3,(H,14,15)

Upstream product

• 108-30-5 succinic acid anhydride 
• 103-73-1 Phenetole 
• 905590-59-2 N-(5-benzyl-4-phenyl-1,3-thiazol-2-yl)-4-(4-ethoxyphenyl)-4-oxobutanamide 
• 905592-32-7 4-(3-ethoxyphenyl)-4-oxobutanoic acid ethyl etser 

Downstream Products

• 905590-63-8 N-(5-benzyl-4-phenyl-1,3-thiazol-2-yl)-4-(3-ethoxyphenyl)-4-oxobutanamide 
• 905590-54-7 4-(3-ethoxyphenyl)-4,4-dimethoxybutanoic acid potassium salt 

Relevant articles and documents

Synthesis of Enantiopure γ-Lactones via a RuPHOX-Ru Catalyzed Asymmetric Hydrogenation of γ-Keto Acids

A RuPHOX?Ru catalyzed asymmetric hydrogenation of γ-keto acids has been developed, affording the corresponding enantiopure γ-lactones in high yields and with up to 97% ee. The reaction could be performed on a gram scale with a relatively low catalyst loading (up to 10000 S/C) under the indicated reaction conditions and the resulting products can be transformed to several enantiopure building blocks, biologically active compounds and enantiopure drugs. (Figure presented.).

AMIDE COMPOUND

The present invention relate to a compound represented by the formula (I) or (II) wherein ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine), ring B is an optionally substituted aromatic ring, ring D is an optionally substituted ring, R1 and R2 are each independently a hydrogen atom or a substituent, R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring, ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N, Ra1 is an optionally substituted hydrocarbon group, and Ra2 and Ra3 are each independently a hydrogen atom or a substituent, or a salt thereof. The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.

AMIDE COMPOUND

Disclosed is a compound represented by the formula (I) or (II) below, or a salt thereof. [In the formulae, ring A represents an optionally substituted ring (which is not a pyrrolidine, piperidine or piperazine); ring B represents an optionally substituted aromatic ring; ring D represents an optionally substituted ring; R1 and R2 independently represent a hydrogen atom or a substituent; R3 represents a hydrogen atom or a C1-6 alkyl group, or alternatively it combines with the ring A to form a non-aromatic ring; ring Aa represents an optionally substituted aromatic hydrocarbon; Y represents CH or N; Ra1 represents an optionally substituted hydrocarbon group; and Ra2 and Ra3 independently represent a hydrogen atom or a substituent.] The compound has a DGAT inhibitory effect and is useful for treatment or improvement of diseases or conditions caused by high expression or high activation of DGAT.